Skip to main content Help with accessibility Skip to main navigation

EMPAGLIFLOZIN tablets (Jardiance®) for symptomatic chronic heart failure with reduced ejection fraction

CCG Approval Status:

Date Added: 28 - Apr - 2022
Body System:

The Pan Mersey Area Prescribing Committee recommends the prescribing of EMPAGLIFLOZIN tablets (Jardiance®) for symptomatic chronic heart failure with reduced ejection fraction, following specialist recommendation in accordance with NICE TA773.

Patient information leaflet: SGLT 2 Inhibitors: Information for patients with heart failure